You're invited

Angela Luttick

360biolabs

Angela Luttick is Executive Vice President, Commercial at 360biolabs, a BioAgilytix company.

Co-founder and Executive Director, Angela leads business development and future expansion activities for 360biolabs. Angela has extensive drug discovery pharmaceutical experience and expertise in early phase drug discovery through to IND filing. With a background in virology and the combination of technical expertise and business acumen, Angela understands a client's requirements from the initial engagement.

Chris Hickey

Nucleus Network

Chris Hickey is Executive Vice President Business Development at Nucleus Network. Chris has dedicated his 16-year career to the services side of the Phase I clinical drug development industry, including operational and business development roles. Having worked within all major biopharma markets including USA, Japan, China, EU and Australia has enabled him to become a trusted advisor to many customers and help them achieve their clinical drug development objectives.

Chris’ deep knowledge of the global early phase drug development industry strengthens the tradition of success of Nucleus Network, our customers and partners in “Advancing Medicines, Improving Lives”.

James Dietrich

Acclime

James is Head of Business Development UK & Europe for Acclime following 10+ years working in International Business Development. Across his career James has worked in multiple sectors including FinTech, Sports Marketing and Recruitment. With a focus on International Business Development, James has great knowledge in helping businesses navigate international expansion.

James joined Acclime to help it continue its rapid growth in helping UK & European businesses access the APAC region. With over 8000 clients globally, Acclime has established itself as a global leader in international professional services.

During his time at Acclime, James has worked extensively within the Life Science sector attending global industry events and speaking to the benefits of the Australian R&D incentive.

Afshin Safavi

Colorado Health & Tech Centers (CHTC)

Dr. Afshin Safavi is a founder, consultant, board member, entrepreneur, and investor in biotechnology, pharmaceutical, animal health, technology, and real-estate sectors with multi-billion-dollar turnovers in biological products and is responsible for multiple drug products in the market today.

He has founded Colorado Health and Tech Centers (CHTC), Novel351k, and BioAgilytix Labs, one of the most successful multi-billion-dollar Contract Research Organizations known internationally. His last four consecutive exits delivered 7 to 200x returns in 5 years or less. He has extensive experience establishing and leading teams in pharmaceutical and manufacturing companies.

Before founding Colorado Health and Tech Centers (CHTC), NOVEL351K, and BioAgilytix Labs, he worked for various organizations, including AAIPharma, Bayer Biologicals, Talecris BioTherapeutics (Grifols), Nobex Corporation, GlaxoSmithKline, and IGEN International. Dr. Safavi obtained his B.S. in Biochemistry from UCLA and his Ph.D. in Biochemistry from the University of Kentucky Medical School. He completed a two-year postdoctoral assignment at the Emory University, Department of Pathology.